ECMO Retrieval Program: What Have We Learned So Far

被引:2
|
作者
Krasivskyi, Ihor [1 ]
Grossmann, Clara [1 ]
Dechow, Marit [1 ]
Djordjevic, Ilija [1 ]
Ivanov, Borko [2 ]
Gerfer, Stephen [1 ]
Bennour, Walid [1 ]
Kuhn, Elmar [1 ]
Sabashnikov, Anton [1 ]
Mader, Navid [1 ]
Eghbalzadeh, Kaveh [1 ]
Wahlers, Thorsten [1 ]
机构
[1] Univ Hosp Cologne, Dept Cardiothorac Surg, D-50937 Cologne, Germany
[2] Helios Hosp Siegburg, Heart Ctr, Dept Cardiothorac Surg, D-53721 Siegburg, Germany
来源
LIFE-BASEL | 2023年 / 13卷 / 01期
关键词
ECMO; cardiogenic shock; mortality; EXTRACORPOREAL MEMBRANE-OXYGENATION; CARDIOGENIC-SHOCK; OUTCOMES; SUPPORT; ADULTS;
D O I
10.3390/life13010157
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used for patients with cardiogenic shock or cardiac arrest. However, survival rates remain low. It is unclear to what extent ECMO patients benefit from the ECMO team learning curve. Therefore, we aimed to analyze our mobile ECMO program patients from the past seven years to evaluate if a learning curve benefits patients' outcomes. We analyzed 111 patients from our databank who were supported with a VA-ECMO and brought to our hospital from January 2015 to December 2021. Patients were divided into two groups: survival (n = 70) and non-survival (n = 41). As expected, complications after ECMO implantation were more severe in the non-survivor group. The incidence of thromboembolic events (p = 0.002), hepatic failure (p < 0.001), renal failure (p = 0.002), dialysis (p = 0.002) and systemic inflammatory response syndrome (SIRS, p = 0.044) occurred significantly more often compared with the survivor group. We were able to show that despite our extensive experience in terms of ECMO retrieval program the high mortality and morbidity rates stay fairly the same over the years. This displays that we have to focus even more on patient selection and ECMO indication.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Brexit: What Have We Learned So Far?
    Besch, Sophia
    Black, James
    SURVIVAL, 2016, 58 (05) : 59 - 67
  • [2] Fukushima - what have we learned so far?
    Kidd, Steve
    NUCLEAR ENGINEERING INTERNATIONAL, 2011, 56 (685): : 12 - 13
  • [3] Levosimendan: What Have We Learned So Far?
    Giulia Villa
    Guido Tavazzi
    Fabio Guarracino
    Fabio Sangalli
    Current Anesthesiology Reports, 2019, 9 : 234 - 241
  • [4] Acrylamide: What we have learned so far
    Coughlin, JR
    FOOD TECHNOLOGY, 2003, 57 (02) : 100 - 100
  • [5] Levosimendan: What Have We Learned So Far?
    Villa, Giulia
    Tavazzi, Guido
    Guarracino, Fabio
    Sangalli, Fabio
    CURRENT ANESTHESIOLOGY REPORTS, 2019, 9 (03) : 234 - 241
  • [6] MORTGAGE PRICING - WHAT HAVE WE LEARNED SO FAR
    HENDERSHOTT, PH
    AREUEA JOURNAL-JOURNAL OF THE AMERICAN REAL ESTATE & URBAN ECONOMICS ASSOCIATION, 1986, 14 (04): : 497 - 509
  • [7] DRUG COURTS - WHAT HAVE WE LEARNED SO FAR
    MAHONEY, B
    JUSTICE SYSTEM JOURNAL, 1994, 17 (01) : 127 - 133
  • [8] Neuroinflammation and autism: what have we learned so far?
    Aytulun, Asli
    Unal, Dilek
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES, 2024,
  • [9] State regulation what have we learned so far?
    Nichols, LM
    JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2000, 25 (01) : 175 - 196
  • [10] Maize allergy: what we have learned so far
    Venter, C.
    Skypala, I.
    Dean, T.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2008, 38 (12): : 1844 - 1846